News EMA Panel Backs Uplizna for Neuromyelitis Optica by Medscape • 2021/11/15 • 0 Comments The immunosuppressant inebilizumab is indicated to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin 4 immunoglobulin G seropositive. International Approvals Full Story →